A treatment combination involving the addition of a form of vitamin A to the current standard treatment regimen for pancreatic cancer is safe for patients, according to an early phase clinical trial led by Queen Mary University of London. Following the encouraging results of this phase I trial (STARPAC), published today in Nature Communications, a second clinical trial called STARPAC2 will now investigate whether the addition of this form of vitamin A, called ATRA, to standard chemotherapy can enhance the efficacy of treatment in patients with pancreatic cancer. STARPAC was launched following research conducted by Professor Kocher's laboratory, which found...